Top Markets
Coin of the day
Organogenesis Holdings Inc. Organogenesis Holdings Inc.

Organogenesis Holdings Inc.

ORGO
Classificação em ações #17996
Organogenesis Holdings Inc. is a U.S.-based regenerative medicine firm that... Organogenesis Holdings Inc. is a U.S.-based regenerative medicine firm that specializes in creating, producing, and marketing innovative therapies for advanced wound management, as well as surgical and sports medicine applications. Within its advanced wound care portfolio, Organogenesis offers several distinct products. These include Affinity and Novachor, both amniotic membrane dressings designed to preserve vital cells, growth factors, and ECM proteins found in natural tissue. Apligraf is a bioengineered living cell therapy that releases a range of healing cytokines and growth factors, while Dermagraft is another bioengineered solution that generates human collagen, ECM, proteins, and cytokines. NuShield provides a wound covering incorporating both amnion and chorion membranes to maintain a spongy intermediate layer. PuraPly acts as an antimicrobial barrier, allowing for flexibility and effective fluid drainage. For the surgical and sports medicine sectors, the company provides products such as NuCel, a dehydrated placental tissue designed for surgical application to promote natural tissue regeneration. ReNu is a cryopreserved suspension aimed at aiding soft tissue recovery. Additionally, FiberOS and OCMP serve as bone void fillers, primarily utilized in orthopedic and neurosurgical procedures. Looking ahead, Organogenesis's product pipeline features PuraPly XT and PuraPly MZ, which are being developed for treating chronic, acute, and open wounds. PuraForce is a bioengineered porcine collagen surgical matrix intended for soft tissue reinforcement. TransCyte, another bioengineered tissue, is in development for addressing partial thickness burns. Organogenesis distributes its offerings to a diverse client base, including hospitals, specialized wound care centers, government institutions, ambulatory surgical centers, and physician offices, leveraging both its direct sales team and independent agencies. Established in 1985, the company maintains its headquarters in Canton, Massachusetts.
Preço da ação
$1.69
Última sincronização: 2026-09-02
Valor de mercado
$216.83M
Variação (1 dia)
3.38%
Variação (1 ano)
-66.03%
País
US
Negociar Organogenesis Holdings Inc. (ORGO)

Categoria

Margem Operacional de Organogenesis Holdings Inc. (ORGO)
Margem Operacional em 2026 TTM: 0.00%
De acordo com os relatórios financeiros mais recentes e o preço das ações da Organogenesis Holdings Inc., a margem operacional atual (TTM) é 0.00%. No final de 2026, a margem operacional era 0.00%.
Histórico da Margem Operacional da Organogenesis Holdings Inc. de 2026 a 2026
Margem Operacional no final de cada ano
Ano Margem Operacional Alterar
Não há dados suficientes para as datas fornecidas.
Margem Operacional de empresas semelhantes ou concorrentes
Empresa Margem Operacional Diferença na Margem Operacional País
0.00% -
DE
0.00% -
DE
0.00% -
JP
22.93% -
IN
0.00% -
CH
O que é a Margem Operacional de uma empresa?
A Margem Operacional é um indicador essencial para avaliar a rentabilidade de uma empresa. Margens operacionais mais altas geralmente são melhores, pois mostram que uma empresa consegue vender seus produtos ou serviços por muito mais do que o custo de produzi-los. É calculada dividindo os lucros da empresa pela sua receita.